Manufacturing and Management of CAR T-Cell Therapy in “COVID-19’s Time”: Central Versus Point of Care Proposals

Manufacturing and Management of CAR T-Cell Therapy in “COVID-19’s Time”: Central Versus Point of Care Proposals

The COVID-19 pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has generated a significant repercussion on the administration of adoptive cell therapies, including chimeric antigen receptor (CAR) T-cells. The closing of borders, the reduction of people transit and the...

Full description

Bibliographic Details
Main Authors: Iñaki Ortiz de Landazuri, Natalia Egri, Guillermo Muñoz-Sánchez, Valentín Ortiz-Maldonado, Victor Bolaño, Carla Guijarro, Mariona Pascal, Manel Juan
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Immunology
Subjects:
chimeric antigen receptor
adoptive cell immunotherapy
SARS-CoV-2 coronavirus
manufacturing process
good manufacturing practice
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.573179/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.573179/full

Similar Items